Medical News

Pfizer Halts Late-Stage Study Into New Lyrica Use

May 7, 2012

Pfizer said Friday it has stopped a late-stage study of its drug Lyrica as a potential treatment for HIV-related nerve pain. In the United States, Lyrica already is approved to treat nerve pain from diabetes, pain following shingles, fibromyalgia, and some seizures in adults with epilepsy. Pfizer has been studying Lyrica's potential use for HIV neuropathy, a condition involving nerve damage marked by burning pain that typically begins in the feet. However, an early analysis of study data found that pain improvements in treated patients were almost identical to those who received a placebo. The study did not raise any safety concerns; Pfizer plans further analysis of the results.

Back to other news for May 2012

Adapted from:
Associated Press

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.